25 XP   0   0   10

SpringWorks Therapeutics Inc
Buy, Hold or Sell?

Let's analyse SpringWorks Therapeutics Inc together

PenkeI guess you are interested in SpringWorks Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of SpringWorks Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about SpringWorks Therapeutics Inc

I send you an email if I find something interesting about SpringWorks Therapeutics Inc.

Quick analysis of SpringWorks Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of SpringWorks Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$8.49
Expected worth in 1 year
$9.41
How sure are you?
21.7%

+ What do you gain per year?

Total Gains per Share
$0.92
Return On Investment
1.9%

For what price can you sell your share?

Current Price per Share
$49.22
Expected price per share
$46.45 - $53.78
How sure are you?
50%

1. Valuation of SpringWorks Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$49.22

Intrinsic Value Per Share

$-65.67 - $-78.08

Total Value Per Share

$-57.19 - $-69.59

2. Growth of SpringWorks Therapeutics Inc (5 min.)




Is SpringWorks Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$626.2m$468.2m$26.5m5.4%

How much money is SpringWorks Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$80.2m-$68m-$12.1m-15.1%
Net Profit Margin-1,433.7%-316,399.2%--

How much money comes from the company's main activities?

3. Financial Health of SpringWorks Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#87 / 1031

Most Revenue
#339 / 1031

Most Profit
#974 / 1031

Most Efficient
#842 / 1031

What can you expect buying and holding a share of SpringWorks Therapeutics Inc? (5 min.)

Welcome investor! SpringWorks Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of SpringWorks Therapeutics Inc.

What can you expect buying and holding a share of SpringWorks Therapeutics Inc?

First you should know what it really means to hold a share of SpringWorks Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of SpringWorks Therapeutics Inc is $49.22. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of SpringWorks Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in SpringWorks Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $8.49. Based on the TTM, the Book Value Change Per Share is $0.23 per quarter. Based on the YOY, the Book Value Change Per Share is $0.46 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of SpringWorks Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.28-2.6%-1.10-2.2%-0.94-1.9%-0.59-1.2%-0.53-1.1%
Usd Book Value Change Per Share3.136.4%0.230.5%0.460.9%0.440.9%0.350.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share3.136.4%0.230.5%0.460.9%0.440.9%0.350.7%
Usd Price Per Share36.50-27.90-33.90-38.90-33.82-
Price to Earnings Ratio-7.14--6.30--9.29--12.51--10.87-
Price-to-Total Gains Ratio11.64--22.61--38.74--87.84--87.84-
Price to Book Ratio4.30-4.16-5.88-6.83-5.94-
Price-to-Total Gains Ratio11.64--22.61--38.74--87.84--87.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share49.22
Number of shares20
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.230.44
Usd Total Gains Per Share0.230.44
Gains per Quarter (20 shares)4.618.75
Gains per Year (20 shares)18.4435.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1018803525
20372607060
305544010595
4074620140130
5092800175165
60111980210200
701291160245235
801481340280270
901661520315305
1001841700350340

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.022.00.04.3%31.023.016.044.3%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%5.014.01.025.0%5.015.03.021.7%33.034.03.047.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.023.00.0%0.00.070.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%5.014.01.025.0%5.015.03.021.7%33.034.03.047.1%

Fundamentals of SpringWorks Therapeutics Inc

About SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Fundamental data was last updated by Penke on 2024-03-22 05:00:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of SpringWorks Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit SpringWorks Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare SpringWorks Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -1,731.6% means that $-17.32 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of SpringWorks Therapeutics Inc:

  • The MRQ is -1,731.6%. The company is making a huge loss. -2
  • The TTM is -1,433.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,731.6%TTM-1,433.7%-297.9%
TTM-1,433.7%YOY-316,399.2%+314,965.4%
TTM-1,433.7%5Y-67,291.1%+65,857.3%
5Y-67,291.1%10Y-58,514.0%-8,777.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,731.6%-159.2%-1,572.4%
TTM-1,433.7%-202.3%-1,231.4%
YOY-316,399.2%-263.0%-316,136.2%
5Y-67,291.1%-452.4%-66,838.7%
10Y-58,514.0%-589.0%-57,925.0%
1.1.2. Return on Assets

Shows how efficient SpringWorks Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare SpringWorks Therapeutics Inc to the Biotechnology industry mean.
  • -13.0% Return on Assets means that SpringWorks Therapeutics Inc generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of SpringWorks Therapeutics Inc:

  • The MRQ is -13.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.0%TTM-14.3%+1.3%
TTM-14.3%YOY-13.9%-0.4%
TTM-14.3%5Y-9.4%-4.9%
5Y-9.4%10Y-9.4%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.0%-12.5%-0.5%
TTM-14.3%-12.2%-2.1%
YOY-13.9%-11.2%-2.7%
5Y-9.4%-13.3%+3.9%
10Y-9.4%-14.6%+5.2%
1.1.3. Return on Equity

Shows how efficient SpringWorks Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare SpringWorks Therapeutics Inc to the Biotechnology industry mean.
  • -15.1% Return on Equity means SpringWorks Therapeutics Inc generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of SpringWorks Therapeutics Inc:

  • The MRQ is -15.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.1%TTM-16.5%+1.5%
TTM-16.5%YOY-15.4%-1.1%
TTM-16.5%5Y-10.0%-6.5%
5Y-10.0%10Y-9.4%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.1%-16.0%+0.9%
TTM-16.5%-15.8%-0.7%
YOY-15.4%-13.9%-1.5%
5Y-10.0%-18.2%+8.2%
10Y-9.4%-19.1%+9.7%

1.2. Operating Efficiency of SpringWorks Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient SpringWorks Therapeutics Inc is operating .

  • Measures how much profit SpringWorks Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare SpringWorks Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -1,807.7% means the company generated $-18.08  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of SpringWorks Therapeutics Inc:

  • The MRQ is -1,807.7%. The company is operating very inefficient. -2
  • The TTM is -1,534.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,807.7%TTM-1,534.4%-273.2%
TTM-1,534.4%YOY-314,781.1%+313,246.7%
TTM-1,534.4%5Y-66,981.2%+65,446.8%
5Y-66,981.2%10Y-58,244.5%-8,736.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,807.7%-299.5%-1,508.2%
TTM-1,534.4%-208.5%-1,325.9%
YOY-314,781.1%-280.2%-314,500.9%
5Y-66,981.2%-459.9%-66,521.3%
10Y-58,244.5%-596.9%-57,647.6%
1.2.2. Operating Ratio

Measures how efficient SpringWorks Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 19.18 means that the operating costs are $19.18 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of SpringWorks Therapeutics Inc:

  • The MRQ is 19.175. The company is inefficient in keeping operating costs low. -1
  • The TTM is 15.705. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ19.175TTM15.705+3.471
TTM15.705YOY3,147.983-3,132.279
TTM15.7055Y669.969-654.264
5Y669.96910Y582.581+87.387
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.1752.817+16.358
TTM15.7053.181+12.524
YOY3,147.9833.609+3,144.374
5Y669.9695.554+664.415
10Y582.5817.396+575.185

1.3. Liquidity of SpringWorks Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if SpringWorks Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.41 means the company has $6.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of SpringWorks Therapeutics Inc:

  • The MRQ is 6.408. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.199. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.408TTM10.199-3.791
TTM10.199YOY12.535-2.337
TTM10.1995Y19.123-8.925
5Y19.12310Y17.185+1.938
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4083.987+2.421
TTM10.1994.440+5.759
YOY12.5355.569+6.966
5Y19.1236.158+12.965
10Y17.1856.492+10.693
1.3.2. Quick Ratio

Measures if SpringWorks Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare SpringWorks Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 10.08 means the company can pay off $10.08 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of SpringWorks Therapeutics Inc:

  • The MRQ is 10.084. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.548. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.084TTM17.548-7.463
TTM17.548YOY20.554-3.007
TTM17.5485Y26.132-8.585
5Y26.13210Y23.264+2.869
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.0843.653+6.431
TTM17.5484.158+13.390
YOY20.5545.515+15.039
5Y26.1326.012+20.120
10Y23.2646.206+17.058

1.4. Solvency of SpringWorks Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of SpringWorks Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare SpringWorks Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.14 means that SpringWorks Therapeutics Inc assets are financed with 13.7% credit (debt) and the remaining percentage (100% - 13.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of SpringWorks Therapeutics Inc:

  • The MRQ is 0.137. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.132. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.137TTM0.132+0.005
TTM0.132YOY0.099+0.033
TTM0.1325Y0.073+0.059
5Y0.07310Y0.147-0.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1370.336-0.199
TTM0.1320.330-0.198
YOY0.0990.267-0.168
5Y0.0730.367-0.294
10Y0.1470.378-0.231
1.4.2. Debt to Equity Ratio

Measures if SpringWorks Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare SpringWorks Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 15.9% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of SpringWorks Therapeutics Inc:

  • The MRQ is 0.159. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.153. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.159TTM0.153+0.006
TTM0.153YOY0.110+0.043
TTM0.1535Y0.078+0.075
5Y0.07810Y0.086-0.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1590.376-0.217
TTM0.1530.398-0.245
YOY0.1100.334-0.224
5Y0.0780.431-0.353
10Y0.0860.476-0.390

2. Market Valuation of SpringWorks Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings SpringWorks Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare SpringWorks Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -7.14 means the investor is paying $-7.14 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of SpringWorks Therapeutics Inc:

  • The EOD is -9.626. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.138. Based on the earnings, the company is expensive. -2
  • The TTM is -6.295. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.626MRQ-7.138-2.488
MRQ-7.138TTM-6.295-0.843
TTM-6.295YOY-9.291+2.995
TTM-6.2955Y-12.506+6.211
5Y-12.50610Y-10.875-1.631
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.626-2.697-6.929
MRQ-7.138-2.422-4.716
TTM-6.295-2.709-3.586
YOY-9.291-4.116-5.175
5Y-12.506-6.257-6.249
10Y-10.875-6.478-4.397
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of SpringWorks Therapeutics Inc:

  • The EOD is -15.031. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.147. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.966. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.031MRQ-11.147-3.885
MRQ-11.147TTM-8.966-2.181
TTM-8.966YOY-15.657+6.691
TTM-8.9665Y-20.088+11.122
5Y-20.08810Y-17.468-2.620
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.031-3.344-11.687
MRQ-11.147-2.939-8.208
TTM-8.966-3.486-5.480
YOY-15.657-5.592-10.065
5Y-20.088-8.464-11.624
10Y-17.468-8.872-8.596
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of SpringWorks Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.30 means the investor is paying $4.30 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of SpringWorks Therapeutics Inc:

  • The EOD is 5.800. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.301. Based on the equity, the company is fair priced.
  • The TTM is 4.163. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD5.800MRQ4.301+1.499
MRQ4.301TTM4.163+0.138
TTM4.163YOY5.876-1.713
TTM4.1635Y6.830-2.667
5Y6.83010Y5.939+0.891
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.8002.198+3.602
MRQ4.3012.042+2.259
TTM4.1632.121+2.042
YOY5.8762.907+2.969
5Y6.8303.682+3.148
10Y5.9394.114+1.825
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of SpringWorks Therapeutics Inc.

3.1. Institutions holding SpringWorks Therapeutics Inc

Institutions are holding 107.466% of the shares of SpringWorks Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31FMR Inc14.64930.030310809235142376415.1699
2023-12-31Vanguard Group Inc8.18110.00486036542111408022.6326
2023-12-31BlackRock Inc7.29420.005538218495645221.6112
2023-12-31Deep Track Capital, LP5.50734.9535406367651724114.5848
2023-12-31Boxer Capital LLC4.63716.2245342154100
2023-12-31Orbimed Advisors, LLC4.36312.34673219359-749229-18.879
2023-12-31Marshall Wace Asset Management Ltd4.09950.18730248591736606134.8032
2023-12-31Maverick Capital Ltd3.89392.10628732162235456350.5168
2023-12-31T. Rowe Price Associates, Inc.3.7630.01362776570122105678.4986
2023-12-31State Street Corporation3.55030.00472619650484541.8845
2023-12-31ArrowMark Colorado Holdings, LLC (ArrowMark Partners)2.84170.84482096808-299474-12.4974
2023-12-31Perceptive Advisors LLC2.65261.5946195724643683028.731
2023-12-31Artal Group S A2.18921.96011615348-201272-11.0795
2023-09-30Deerfield Management Co2.14070.804615795742250.0142
2023-12-31Pictet Asset Manangement SA2.11210.0627155848750463047.8841
2023-12-31Geode Capital Management, LLC1.92320.0054141908823697820.047
2023-12-31Dimensional Fund Advisors, Inc.1.31240.0103968405-42964-4.2481
2023-12-31Goldman Sachs Group Inc1.25030.00392255033007355.7107
2023-12-31Fiera Capital Corporation1.21090.10018934565220.0585
2023-12-31Woodline Partners LP1.08720.3184802182610809319.172
Total 78.659121.580158039976+10080237+17.4%

3.2. Funds holding SpringWorks Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Growth Compy Commingled Pl O6.07890.2764485417777881.7648
2024-01-31Fidelity Growth Company Fund4.59480.27283390355-19790-0.5803
2024-02-29Vanguard Total Stock Mkt Idx Inv2.60240.00611920253-5763-0.2992
2024-02-29iShares Russell 2000 ETF2.20110.12831624150-265-0.0163
2024-02-29Vanguard Small Cap Index2.13970.05531578809146450.9363
2024-02-29SPDR® S&P Biotech ETF1.83860.84391356633253231.9021
2024-01-31Fidelity Growth Company K61.60710.31221185854-25033-2.0673
2023-12-31T. Rowe Price Health Sciences1.42320.2605105012525906432.7489
2024-01-31Fidelity Series Growth Company1.29920.284795864838990.4084
2023-12-31US Small-Cap Growth II Equity Comp1.29790.1408957651551115135.5636
2023-12-31T. Rowe Price New Horizons1.29790.1413957651551115135.5636
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.25750.04489278726900.0744
2024-02-29Vanguard Small Cap Growth Index Inv1.2010.1251886168147431.6918
2024-01-31Fidelity Select Biotechnology1.16150.8198857009311853.7762
2024-01-31BNP Paribas Health Cr Innovtr Cl Cap0.9841.8918726031-1572-0.2161
2023-12-31Fidelity Small Cap Index0.90530.09596679849538416.6581
2023-11-30MEDICAL BioHealth EUR Acc0.88922.7609656106380006.1478
2023-12-31Vanguard Explorer Inv0.88050.1109649666-54451-7.7332
2024-02-29iShares Russell 2000 Growth ETF0.79930.2559589753-686-0.1162
2023-10-31Pictet-Biotech P USD0.79631.0525587560-10779-1.8015
Total 35.25549.879526013695+1544612+5.9%

3.3. Insider Transactions

Insiders are holding 2.876% of the shares of SpringWorks Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-16Daniel PichlSELL1500050.1
2023-07-19Julie HambletonSELL241829.31
2023-06-20Julie HambletonSELL240026.92

4. Summary

4.1. Key Performance Indicators

The key performance indicators of SpringWorks Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--3.1350.230+1260%0.460+581%0.437+617%0.346+805%
Book Value Per Share--8.4876.707+27%6.346+34%5.576+52%4.883+74%
Current Ratio--6.40810.199-37%12.535-49%19.123-66%17.185-63%
Debt To Asset Ratio--0.1370.132+4%0.099+38%0.073+88%0.147-7%
Debt To Equity Ratio--0.1590.153+4%0.110+44%0.078+105%0.086+86%
Dividend Per Share----0%-0%-0%-0%
Eps---1.278-1.101-14%-0.940-26%-0.593-54%-0.531-58%
Free Cash Flow Per Share---0.819-0.780-5%-0.582-29%-0.415-49%-0.369-55%
Free Cash Flow To Equity Per Share--3.2350.225+1336%0.572+465%0.427+658%0.427+658%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---78.076--------
Intrinsic Value_10Y_min---65.675--------
Intrinsic Value_1Y_max---3.192--------
Intrinsic Value_1Y_min---3.132--------
Intrinsic Value_3Y_max---13.120--------
Intrinsic Value_3Y_min---12.454--------
Intrinsic Value_5Y_max---27.304--------
Intrinsic Value_5Y_min---25.039--------
Market Cap3631786296.000+26%2693218200.0002058282786.000+31%2501372520.000+8%2870085159.600-6%2495726225.739+8%
Net Profit Margin---17.316-14.337-17%-3163.992+18172%-672.911+3786%-585.140+3279%
Operating Margin---18.077-15.344-15%-3147.811+17314%-669.812+3605%-582.445+3122%
Operating Ratio--19.17515.705+22%3147.983-99%669.969-97%582.581-97%
Pb Ratio5.800+26%4.3014.163+3%5.876-27%6.830-37%5.939-28%
Pe Ratio-9.626-35%-7.138-6.295-12%-9.291+30%-12.506+75%-10.875+52%
Price Per Share49.220+26%36.50027.895+31%33.900+8%38.897-6%33.823+8%
Price To Free Cash Flow Ratio-15.031-35%-11.147-8.966-20%-15.657+40%-20.088+80%-17.468+57%
Price To Total Gains Ratio15.700+26%11.643-22.611+294%-38.744+433%-87.844+854%-87.844+854%
Quick Ratio--10.08417.548-43%20.554-51%26.132-61%23.264-57%
Return On Assets---0.130-0.143+10%-0.139+7%-0.094-28%-0.094-28%
Return On Equity---0.151-0.165+10%-0.154+3%-0.100-34%-0.094-38%
Total Gains Per Share--3.1350.230+1260%0.460+581%0.437+617%0.346+805%
Usd Book Value--626219000.000494870750.000+27%468282500.000+34%411422250.000+52%360268521.739+74%
Usd Book Value Change Per Share--3.1350.230+1260%0.460+581%0.437+617%0.346+805%
Usd Book Value Per Share--8.4876.707+27%6.346+34%5.576+52%4.883+74%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.278-1.101-14%-0.940-26%-0.593-54%-0.531-58%
Usd Free Cash Flow---60403000.000-57545000.000-5%-42939750.000-29%-30638950.000-49%-27195804.348-55%
Usd Free Cash Flow Per Share---0.819-0.780-5%-0.582-29%-0.415-49%-0.369-55%
Usd Free Cash Flow To Equity Per Share--3.2350.225+1336%0.572+465%0.427+658%0.427+658%
Usd Market Cap3631786296.000+26%2693218200.0002058282786.000+31%2501372520.000+8%2870085159.600-6%2495726225.739+8%
Usd Price Per Share49.220+26%36.50027.895+31%33.900+8%38.897-6%33.823+8%
Usd Profit---94322000.000-80206250.000-15%-68057250.000-28%-43542200.000-54%-38494000.000-59%
Usd Revenue--5447000.0005604500.000-3%1747500.000+212%3246450.000+68%2823000.000+93%
Usd Total Gains Per Share--3.1350.230+1260%0.460+581%0.437+617%0.346+805%
 EOD+6 -2MRQTTM+17 -16YOY+20 -135Y+16 -1710Y+19 -14

4.2. Fundamental Score

Let's check the fundamental score of SpringWorks Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-9.626
Price to Book Ratio (EOD)Between0-15.800
Net Profit Margin (MRQ)Greater than0-17.316
Operating Margin (MRQ)Greater than0-18.077
Quick Ratio (MRQ)Greater than110.084
Current Ratio (MRQ)Greater than16.408
Debt to Asset Ratio (MRQ)Less than10.137
Debt to Equity Ratio (MRQ)Less than10.159
Return on Equity (MRQ)Greater than0.15-0.151
Return on Assets (MRQ)Greater than0.05-0.130
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of SpringWorks Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.051
Ma 20Greater thanMa 5050.193
Ma 50Greater thanMa 10047.641
Ma 100Greater thanMa 20039.089
OpenGreater thanClose50.130
Total5/5 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -767605-162-190-35239-3131,5041,191



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets725,788
Total Liabilities99,569
Total Stockholder Equity626,219
 As reported
Total Liabilities 99,569
Total Stockholder Equity+ 626,219
Total Assets = 725,788

Assets

Total Assets725,788
Total Current Assets500,912
Long-term Assets224,876
Total Current Assets
Cash And Cash Equivalents 176,053
Short-term Investments 303,149
Net Receivables 5,930
Inventory 3,103
Other Current Assets 12,677
Total Current Assets  (as reported)500,912
Total Current Assets  (calculated)500,912
+/-0
Long-term Assets
Property Plant Equipment 24,087
Long Term Investments 185,341
Intangible Assets 11,200
Long-term Assets Other 4,248
Long-term Assets  (as reported)224,876
Long-term Assets  (calculated)224,876
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities78,170
Long-term Liabilities21,399
Total Stockholder Equity626,219
Total Current Liabilities
Short-term Debt 1,061
Accounts payable 7,396
Other Current Liabilities 65,569
Total Current Liabilities  (as reported)78,170
Total Current Liabilities  (calculated)74,026
+/- 4,144
Long-term Liabilities
Capital Lease Obligations 7,057
Long-term Liabilities  (as reported)21,399
Long-term Liabilities  (calculated)7,057
+/- 14,342
Total Stockholder Equity
Common Stock7
Retained Earnings -895,034
Accumulated Other Comprehensive Income 1,191
Other Stockholders Equity 1,520,055
Total Stockholder Equity (as reported)626,219
Total Stockholder Equity (calculated)626,219
+/-0
Other
Capital Stock7
Cash and Short Term Investments 479,202
Common Stock Shares Outstanding 73,487
Current Deferred Revenue4,144
Liabilities and Stockholders Equity 725,788
Net Debt -168,996
Net Invested Capital 626,219
Net Working Capital 422,742
Property Plant and Equipment Gross 26,745
Short Long Term Debt Total 7,057



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-03-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
76,161
80,706
82,289
80,462
74,049
72,960
75,032
73,158
73,067
72,710
82,670
76,582
75,572
72,911
48,636
41,721
40,697
40,039
39,864
44,947
43,931
42,405
41,195
39,641
39,051
36,020
35,688
35,501
35,145
36,187
37,519
37,267
40,726
42,950
41,348
37,285
34,379
36,504
38,263
38,911
38,614
41,360
48,349
50,590
51,827
51,755
52,540
0
0
48,390
194,632
194,632
348,395
334,831
317,408
301,020
286,100
576,191
554,588
520,428
495,275
452,494
405,580
365,919
681,554
630,242
569,197
517,329
467,654
725,788
725,788467,654517,329569,197630,242681,554365,919405,580452,494495,275520,428554,588576,191286,100301,020317,408334,831348,395194,632194,63248,3900052,54051,75551,82750,59048,34941,36038,61438,91138,26336,50434,37937,28541,34842,95040,72637,26737,51936,18735,14535,50135,68836,02039,05139,64141,19542,40543,93144,94739,86440,03940,69741,72148,63672,91175,57276,58282,67072,71073,06773,15875,03272,96074,04980,46282,28980,70676,161
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,208
33,041
0
0
47,030
188,179
188,179
344,514
331,361
313,642
293,796
278,902
513,398
481,514
466,991
433,013
382,910
355,951
341,999
657,287
599,760
537,657
483,901
432,383
500,912
500,912432,383483,901537,657599,760657,287341,999355,951382,910433,013466,991481,514513,398278,902293,796313,642331,361344,514188,179188,17947,0300033,04132,208000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,387
2,937
4,775
6,492
4,362
7,524
11,673
10,768
7,776
10,488
12,845
12,454
13,309
13,130
15,573
13,776
11,981
13,400
12,862
0
0
45,648
185,291
185,291
343,825
327,652
311,075
226,666
84,831
147,089
95,426
84,571
93,852
103,961
81,933
69,571
476,429
67,490
102,401
115,001
98,895
176,053
176,05398,895115,001102,40167,490476,42969,57181,933103,96193,85284,57195,426147,08984,831226,666311,075327,652343,825185,291185,29145,6480012,86213,40011,98113,77615,57313,13013,30912,45412,84510,4887,77610,76811,6737,5244,3626,4924,7752,9373,3870000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
222
625
657
294
316
1,645
1,493
282
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
64,567
191,988
361,395
381,985
378,206
334,060
269,540
266,338
264,970
175,514
524,722
425,740
361,706
323,524
303,149
303,149323,524361,706425,740524,722175,514264,970266,338269,540334,060378,206381,985361,395191,98864,56700000000000000000002821,4931,6453162946576252220000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,995
11,393
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,930
5,930000000000000000000000011,39310,995000000000000000000000000000000000000000000000
       Other Current Assets 
1,454
1,928
1,498
2,008
2,311
2,004
1,606
3,471
2,932
2,512
2,816
4,310
3,873
3,424
2,815
2,617
4,128
3,420
2,870
1,757
2,354
1,337
1,056
982
909
866
1,492
1,064
893
809
781
837
1,106
854
751
745
1,213
1,180
1,302
1,479
1,216
1,227
1,401
3,918
3,803
5,177
4,820
0
0
1,382
0
2,888
689
3,709
2,567
2,563
2,083
4,914
4,103
4,214
5,101
9,409
7,680
7,458
5,344
7,548
9,516
7,194
9,964
12,677
12,6779,9647,1949,5167,5485,3447,4587,6809,4095,1014,2144,1034,9142,0832,5632,5673,7096892,88801,382004,8205,1773,8033,9181,4011,2271,2161,4791,3021,1801,2137457518541,1068377818098931,0641,4928669099821,0561,3372,3541,7572,8703,4204,1282,6172,8153,4243,8734,3102,8162,5122,9323,4711,6062,0042,3112,0081,4981,9281,454
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,279
15,282
0
0
1,360
0
6,453
3,881
3,470
3,766
7,224
7,198
62,793
73,074
53,437
62,262
69,584
49,629
23,920
24,267
30,482
31,540
33,428
35,271
224,876
224,87635,27133,42831,54030,48224,26723,92049,62969,58462,26253,43773,07462,7937,1987,2243,7663,4703,8816,45301,3600015,28215,279000000000000000000000000000000000000000000000
       Property Plant Equipment 
46,446
49,762
48,700
49,884
48,876
48,128
48,026
47,841
47,326
48,368
49,553
50,251
49,761
50,983
28,793
21,787
20,468
19,988
19,370
21,110
19,596
18,007
17,523
16,857
16,929
17,338
16,689
17,232
17,020
16,720
17,045
17,071
17,916
17,623
15,596
15,012
13,895
13,940
14,233
14,393
13,166
12,526
15,309
15,235
15,560
15,279
15,282
0
0
317
799
799
820
795
885
1,072
1,176
3,019
2,721
2,496
3,331
4,197
11,391
14,325
16,390
18,269
22,330
25,001
27,389
24,087
24,08727,38925,00122,33018,26916,39014,32511,3914,1973,3312,4962,7213,0191,1761,0728857958207997993170015,28215,27915,56015,23515,30912,52613,16614,39314,23313,94013,89515,01215,59617,62317,91617,07117,04516,72017,02017,23216,68917,33816,92916,85717,52318,00719,59621,11019,37019,98820,46821,78728,79350,98349,76150,25149,55348,36847,32647,84148,02648,12848,87649,88448,70049,76246,446
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,488
1,839
1,854
1,854
366
366
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000003663661,8541,8541,8391,48800000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,500
3,500
999
976
876
4,147
4,017
57,207
67,241
48,157
55,915
62,113
35,021
6,358
4,873
8,987
5,714
4,814
3,789
185,341
185,3413,7894,8145,7148,9874,8736,35835,02162,11355,91548,15767,24157,2074,0174,1478769769993,5003,50000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
700
0
0
0
700
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,488
2,876
2,755
2,694
723
712
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,200
11,20000000000000000000000007127232,6942,7552,8761,488000000000000000000000000000007000007000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,043
0
2,154
2,062
1,699
2,005
2,005
2,005
2,567
3,112
2,784
3,016
3,274
3,217
3,237
3,004
3,226
3,496
3,613
4,093
4,248
4,2484,0933,6133,4963,2263,0043,2373,2173,2743,0162,7843,1122,5672,0052,0052,0051,6992,0622,15401,0430000000000000000000000000000000000000000000000000
> Total Liabilities 
52,675
58,020
61,107
60,324
55,347
52,376
51,336
46,706
44,781
41,168
35,875
36,108
36,258
34,551
33,168
40,000
47,276
45,417
42,876
30,374
28,059
26,162
25,084
23,702
23,937
21,721
24,259
23,655
23,060
23,247
23,839
20,574
21,077
20,979
19,539
15,877
11,668
11,571
12,097
11,758
10,841
11,164
16,037
13,781
12,749
12,929
13,990
0
0
67,759
10,999
10,999
11,076
12,759
9,274
10,146
13,345
19,133
19,891
23,845
28,597
30,098
28,776
40,185
69,154
72,050
62,273
65,888
72,755
99,569
99,56972,75565,88862,27372,05069,15440,18528,77630,09828,59723,84519,89119,13313,34510,1469,27412,75911,07610,99910,99967,7590013,99012,92912,74913,78116,03711,16410,84111,75812,09711,57111,66815,87719,53920,97921,07720,57423,83923,24723,06023,65524,25921,72123,93723,70225,08426,16228,05930,37442,87645,41747,27640,00033,16834,55136,25836,10835,87541,16844,78146,70651,33652,37655,34760,32461,10758,02052,675
   > Total Current Liabilities 
42,111
47,456
51,812
59,557
54,586
51,623
50,592
30,077
29,044
25,887
23,513
23,883
23,963
22,716
21,942
22,644
20,164
17,202
14,799
15,003
13,982
13,152
12,406
11,952
12,226
10,067
12,978
12,318
12,113
12,452
12,932
9,730
10,036
12,561
12,015
8,862
7,842
7,803
8,374
8,342
7,697
8,216
12,329
10,158
9,174
9,594
10,907
0
0
3,677
10,027
10,027
10,195
11,970
8,582
9,551
12,752
17,610
18,729
23,013
28,099
29,969
23,238
34,914
49,494
51,049
37,753
41,910
50,283
78,170
78,17050,28341,91037,75351,04949,49434,91423,23829,96928,09923,01318,72917,61012,7529,5518,58211,97010,19510,02710,0273,6770010,9079,5949,17410,15812,3298,2167,6978,3428,3747,8037,8428,86212,01512,56110,0369,73012,93212,45212,11312,31812,97810,06712,22611,95212,40613,15213,98215,00314,79917,20220,16422,64421,94222,71623,96323,88323,51325,88729,04430,07750,59251,62354,58659,55751,81247,45642,111
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,048
970
0
0
0
0
0
0
0
0
0
0
1,375
1,244
1,251
1,257
1,162
327
511
733
483
386
811
1,161
1,061
1,0611,1618113864837335113271,1621,2571,2511,2441,37500000000009701,048000000000000000000000000000000000000000000000
       Accounts payable 
13,660
15,418
18,020
16,857
14,047
12,800
11,643
10,338
8,757
7,554
7,601
9,244
8,408
5,100
4,783
6,315
4,373
3,509
2,684
2,544
2,536
1,984
930
1,402
2,551
992
1,543
955
1,155
1,426
1,411
964
3,353
2,293
1,304
596
1,232
938
1,190
1,258
1,419
1,554
2,295
2,628
1,973
8,668
10,066
0
0
774
2,144
2,144
2,157
2,654
1,617
909
1,064
1,350
2,229
3,904
2,498
3,429
1,654
2,191
4,586
8,010
6,990
3,454
5,546
7,396
7,3965,5463,4546,9908,0104,5862,1911,6543,4292,4983,9042,2291,3501,0649091,6172,6542,1572,1442,1447740010,0668,6681,9732,6282,2951,5541,4191,2581,1909381,2325961,3042,2933,3539641,4111,4261,1559551,5439922,5511,4029301,9842,5362,5442,6843,5094,3736,3154,7835,1008,4089,2447,6017,5548,75710,33811,64312,80014,04716,85718,02015,41813,660
       Other Current Liabilities 
4,998
6,517
7,380
7,551
8,014
7,983
8,225
8,450
8,102
7,362
6,067
7,140
8,164
8,577
7,944
7,443
8,725
7,909
7,682
8,021
7,165
6,892
7,153
6,237
5,508
4,865
7,409
7,308
6,890
6,947
7,403
7,320
5,421
6,228
6,746
6,048
5,491
5,649
6,043
6,146
5,593
5,962
6,845
6,349
6,109
6,132
6,743
0
0
2,903
349
7,883
8,038
9,316
6,965
8,642
11,688
14,885
15,256
17,858
24,344
25,378
21,257
32,212
44,175
39,242
28,687
35,281
40,332
65,569
65,56940,33235,28128,68739,24244,17532,21221,25725,37824,34417,85815,25614,88511,6888,6426,9659,3168,0387,8833492,903006,7436,1326,1096,3496,8455,9625,5936,1466,0435,6495,4916,0486,7466,2285,4217,3207,4036,9476,8907,3087,4094,8655,5086,2377,1536,8927,1658,0217,6827,9098,7257,4437,9448,5778,1647,1406,0677,3628,1028,4508,2257,9838,0147,5517,3806,5174,998
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,213
2,954
0
0
64,082
0
972
881
789
692
595
593
1,523
1,162
832
498
129
5,538
5,271
19,660
21,001
24,520
23,978
22,472
21,399
21,39922,47223,97824,52021,00119,6605,2715,5381294988321,1621,523593595692789881972064,082002,9543,213000000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,213
2,954
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000002,9543,213000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
545
767
761
753
744
2,116
1,937
1,920
1,907
2,972
2,987
2,300
2,055
3,698
11,621
13,287
13,650
3,727
3,278
3,154
3,490
2,960
2,983
2,822
2,737
2,769
2,784
2,581
2,619
2,567
2,578
2,587
2,594
2,514
135
110
84
58
29
0
0
112
116
122
129
0
0
0
972
972
881
789
692
595
593
164
131
131
131
0
0
0
14,660
16,233
17,856
0
0
0
00017,85616,23314,660000131131131164593595692789881972972000129122116112002958841101352,5142,5942,5872,5782,5672,6192,5812,7842,7692,7372,8222,9832,9603,4903,1543,2783,72713,65013,28711,6213,6982,0552,3002,9872,9721,9071,9201,9372,11674475376176754500
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
700
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000070000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
23,486
22,686
21,182
20,138
18,702
20,584
23,696
26,452
28,286
31,542
46,795
40,474
39,314
38,360
15,468
1,721
0
0
0
14,573
15,872
16,243
16,111
15,939
15,114
14,299
11,429
11,846
12,085
12,940
13,680
16,693
19,649
21,971
21,809
21,408
22,711
24,933
26,166
27,153
27,773
29,880
32,100
36,836
39,205
34,016
33,740
-4,639
0
-19,369
-37,539
183,633
337,319
322,072
308,134
290,874
272,755
557,058
534,697
496,583
466,678
422,396
376,804
325,734
612,400
558,192
506,924
451,441
394,899
626,219
626,219394,899451,441506,924558,192612,400325,734376,804422,396466,678496,583534,697557,058272,755290,874308,134322,072337,319183,633-37,539-19,3690-4,63933,74034,01639,20536,83632,10029,88027,77327,15326,16624,93322,71121,40821,80921,97119,64916,69313,68012,94012,08511,84611,42914,29915,11415,93916,11116,24315,87214,5730001,72115,46838,36039,31440,47446,79531,54228,28626,45223,69620,58418,70220,13821,18222,68623,486
   Common Stock
8
8
8
8
8
8
8
8
9
9
12
12
12
13
13
13
13
13
13
26
26
27
27
27
27
27
27
27
27
28
28
28
28
28
29
29
29
29
29
29
29
29
29
29
29
29
29
0
0
0
0
3
4
4
4
4
4
5
5
5
5
5
5
5
6
6
6
6
6
7
76666655555554444430000292929292929292929292929292828282828272727272727272726261313131313131212129988888888
   Retained Earnings Total Equity00000000000000000000000-49,033-49,244000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-21
0
-84
-348,395
-213
-213
-44
25
41
53
25
24
-312
-1,458
-1,819
-1,515
-767
-162
-352
-313
1,191
1,191-313-352-162-767-1,515-1,819-1,458-3122425534125-44-213-213-348,395-840-210000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
78,791
78,957
0
0
0
0
2,440
394,127
395,097
396,453
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000396,453395,097394,1272,440000078,95778,791000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000-312-620-693-839-1,043-1,145-1,474
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,440
3,787
0
0
1,069
0
223,609
394,127
395,097
396,453
399,130
402,601
675,615
683,029
691,953
703,090
715,216
732,571
750,912
1,109,661
1,128,883
1,150,430
1,173,062
1,195,918
1,520,055
1,520,0551,195,9181,173,0621,150,4301,128,8831,109,661750,912732,571715,216703,090691,953683,029675,615402,601399,130396,453395,097394,127223,60901,069003,7874,440000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue5,447
Cost of Revenue-422
Gross Profit5,0255,025
 
Operating Income (+$)
Gross Profit5,025
Operating Expense-348,038
Operating Income-343,013-343,013
 
Operating Expense (+$)
Research Development150,487
Selling General Administrative197,551
Selling And Marketing Expenses0
Operating Expense348,038348,038
 
Net Interest Income (+$)
Interest Income22,147
Interest Expense-0
Other Finance Cost-0
Net Interest Income22,147
 
Pretax Income (+$)
Operating Income-343,013
Net Interest Income22,147
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-325,104-337,975
EBIT - interestExpense = -343,013
-348,051
-325,104
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-343,013-325,104
Earnings Before Interest and Taxes (EBITDA)-341,346
 
After tax Income (+$)
Income Before Tax-325,104
Tax Provision-0
Net Income From Continuing Ops-304,960-325,104
Net Income-325,104
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses348,460
Total Other Income/Expenses Net-5,038-22,147
 

Technical Analysis of SpringWorks Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of SpringWorks Therapeutics Inc. The general trend of SpringWorks Therapeutics Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine SpringWorks Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of SpringWorks Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 52.52 < 53.57 < 53.78.

The bearish price targets are: 47.51 > 47.32 > 46.45.

Tweet this
SpringWorks Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of SpringWorks Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

SpringWorks Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of SpringWorks Therapeutics Inc. The current macd is 0.5473364.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the SpringWorks Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for SpringWorks Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the SpringWorks Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
SpringWorks Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartSpringWorks Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of SpringWorks Therapeutics Inc. The current adx is 19.00.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy SpringWorks Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
SpringWorks Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of SpringWorks Therapeutics Inc. The current sar is 52.43.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
SpringWorks Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of SpringWorks Therapeutics Inc. The current rsi is 50.05. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
SpringWorks Therapeutics Inc Daily Relative Strength Index (RSI) ChartSpringWorks Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of SpringWorks Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the SpringWorks Therapeutics Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
SpringWorks Therapeutics Inc Daily Stochastic Oscillator ChartSpringWorks Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of SpringWorks Therapeutics Inc. The current cci is -12.12254689.

SpringWorks Therapeutics Inc Daily Commodity Channel Index (CCI) ChartSpringWorks Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of SpringWorks Therapeutics Inc. The current cmo is -6.0409244.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
SpringWorks Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartSpringWorks Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of SpringWorks Therapeutics Inc. The current willr is -63.46153846.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that SpringWorks Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
SpringWorks Therapeutics Inc Daily Williams %R ChartSpringWorks Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of SpringWorks Therapeutics Inc. The current atr is 2.50963586.

SpringWorks Therapeutics Inc Daily Average True Range (ATR) ChartSpringWorks Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of SpringWorks Therapeutics Inc. The current obv is 25,420,606.

SpringWorks Therapeutics Inc Daily On-Balance Volume (OBV) ChartSpringWorks Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of SpringWorks Therapeutics Inc. The current mfi is 49.44.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
SpringWorks Therapeutics Inc Daily Money Flow Index (MFI) ChartSpringWorks Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for SpringWorks Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

SpringWorks Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of SpringWorks Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.051
Ma 20Greater thanMa 5050.193
Ma 50Greater thanMa 10047.641
Ma 100Greater thanMa 20039.089
OpenGreater thanClose50.130
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of SpringWorks Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on SpringWorks Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about SpringWorks Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about SpringWorks Therapeutics Inc

I send you an email if I find something interesting about SpringWorks Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about SpringWorks Therapeutics Inc.

Receive notifications about SpringWorks Therapeutics Inc in your mailbox!